Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Teva snags new CEO from Lundbeck
by Ryan Cross
September 18, 2017
| A version of this story appeared in
Volume 95, Issue 37
The indebted generics giant Teva Pharmaceutical has ended a seven-month search for its fourth CEO in six years, nabbing Kåre Schultz from the same role at the neuroscience drug developer Lundbeck and quelling rumors that AstraZeneca’s CEO would take the job. Schultz will move to Teva’s headquarters in Israel, where he will likely face discussions about dividing the firm into two entities, one focused on generics and the other on new drug development. Lundbeck’s stock fell on the news, while Teva’s began rebounding after a 15-year low.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter